Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Biomarker Research

Background:

• Pre-eclampsia (PE) is a leading cause of maternal and fetal morbidity.
• Early detection of PE is crucial for timely intervention and improved outcomes.
• Current screening methods have limitations in accuracy and timing.

Purpose of the Study:

• To evaluate the performance of a combined screening approach for pre-eclampsia (PE).
• To assess the efficacy of maternal factors, soluble endoglin (sEng), pregnancy-associated plasma protein-A (PAPP-A), placental growth factor (PlGF), and uterine artery lowest pulsatility index (L-PI) in early PE detection.
• To determine the optimal combination of these markers for predicting PE at 11-13 weeks gestation.

Main Methods:

• A prospective study involving singleton pregnancies.
• Measurement of uterine artery L-PI, sEng, PAPP-A, and PlGF at 11-13 weeks gestation.
• Comparison of marker levels and screening performance in pregnancies that developed early PE, late PE, and unaffected controls.

Main Results:

• In early PE, elevated sEng and uterine artery L-PI, with decreased PAPP-A and PlGF, were observed compared to controls.
• In late PE, decreased PlGF and increased uterine artery L-PI were noted, but sEng and PAPP-A showed no significant difference.
• A combination of maternal factors, sEng, PlGF, and uterine artery L-PI achieved a 96.3% detection rate for early PE with a 10% false-positive rate.

Conclusions:

• A multi-marker screening strategy incorporating maternal factors, sEng, PlGF, and uterine artery L-PI is highly effective for early PE detection.
• This combined approach offers a promising tool for identifying pregnancies at high risk for early pre-eclampsia.
• Implementation of this screening protocol could lead to improved management and outcomes for pre-eclampsia.